Compound Radar

Medline Inc. (MDLN) Stock Analysis

Price $34.69
Market cap $46.67B
Next earnings Nov 4, 2026
Entry status Wait

Last updated Sep 8, 2026

Health Check

Last analyzed Sep 7, 2026

47
47/100 Speculative
  • Financial Health 50
  • Profitability 45
  • Business Quality 50
  • Balance Sheet 40
  • Cash Flow 45

Why this rating?

Health 47/100 — Speculative

Strongest Financial Health 50/100
Softest Balance Sheet 40/100
Wait

Entry timing is weak right now. Quality may be fine; the setup is not.

Company overview

Medline Inc. (MDLN) is a Medical Instruments & Supplies company in the Healthcare sector. Compound Radar rates Medline Inc. 47/100 (Speculative) due to solid business quality, steady revenue growth, and elevated leverage.

Investment profile

  • Quality Moderate
  • Growth Moderate
  • Balance Sheet Stretched
  • Valuation Fair

Financial highlights

Valuation

  • P/E 43.36
  • Forward P/E 21.87
  • EV/Revenue 1.66

Profitability

  • Revenue Growth 11.6%
  • Gross Margin 25.1%
  • Operating Margin 0.8%
  • Net Margin 2.3%
  • ROE 4.9%

Financial strength

  • Cash $2.70B
  • Debt $12.64B
  • Net Cash $-9.94B
  • Free Cash Flow $1.30B
  • Current Ratio 4.33

Similar companies

Peers in Medical Instruments & Supplies, ranked by Financial Health.

Company Ticker
Price Current price

Latest quoted price for the name. Helps anchor the setup in today’s market level.

Health Entry

View all in Medical Instruments & Supplies →

FAQ

How Compound Radar scores and tracks Medline Inc. (MDLN).

View Methodology & FAQ →